The radiosensitizing effects of Nelfinavir on pancreatic cancer with and without pancreatic stellate cells. Issue 2 (May 2016)
- Record Type:
- Journal Article
- Title:
- The radiosensitizing effects of Nelfinavir on pancreatic cancer with and without pancreatic stellate cells. Issue 2 (May 2016)
- Main Title:
- The radiosensitizing effects of Nelfinavir on pancreatic cancer with and without pancreatic stellate cells
- Authors:
- Al-Assar, Osama
Bittner, Martin-Immanuel
Lunardi, Serena
Stratford, Michael R.
McKenna, W. Gillies
Brunner, Thomas B. - Abstract:
- Abstract: Aims: We have previously shown in a phase I trial that nelfinavir (NFV) is safe with chemoradiation in PDAC with good signs for efficacy. Reverse translationally, we aimed to test the influence of PSCs on nelfinavir mediated radiosensitization to PDAC preclinically, because PDAC is very rich in desmoplasia and PSCs are known to mediate radioresistance. Methods: In a direct co-culture model of several PDAC cell lines with PSC we performed clonogenic assays +/− nelfinavir. This was repeated exposing cells to hypoxic conditions. In xenograft PDAC tumors we tested radiation +/− nelfinavir +/− PSC. Results: NFV sensitized both, PDAC only and PDAC cocultured with PSC (PDAC: Panc-1, MiaPaCa-2, PSN-1). In Panc-1 and PSN-1 this effect was larger +PSC compared to −PSC. Human pancreatic stellate cells (hPSC) were also sensitized by NFV which reduced p-FAK levels in hPSC, an effect that we previously found to sensitize specifically PDAC/PSC coculture. Contrarily, LY294002 reduced p-Akt in PSC (hPSC and LTC-14) but had no impact on PSC radiation survival. In vitro, nelfinavir sensitized Panc-1 and PSN-1 under normoxic and hypoxic conditions. In PSN-1 xenografts, +PSC led to faster tumor regrowth after radiation vs −PSC. The regrowth delay effect of nelfinavir after radiation was dramatically larger +PSC vs −PSC (time to reach 250 mm 3 183% vs 22%). Conclusion: NFV mediated radiosensitization in PDAC with stroma is partly mediated by p-FAK inhibition (Chen et al., 2013). InAbstract: Aims: We have previously shown in a phase I trial that nelfinavir (NFV) is safe with chemoradiation in PDAC with good signs for efficacy. Reverse translationally, we aimed to test the influence of PSCs on nelfinavir mediated radiosensitization to PDAC preclinically, because PDAC is very rich in desmoplasia and PSCs are known to mediate radioresistance. Methods: In a direct co-culture model of several PDAC cell lines with PSC we performed clonogenic assays +/− nelfinavir. This was repeated exposing cells to hypoxic conditions. In xenograft PDAC tumors we tested radiation +/− nelfinavir +/− PSC. Results: NFV sensitized both, PDAC only and PDAC cocultured with PSC (PDAC: Panc-1, MiaPaCa-2, PSN-1). In Panc-1 and PSN-1 this effect was larger +PSC compared to −PSC. Human pancreatic stellate cells (hPSC) were also sensitized by NFV which reduced p-FAK levels in hPSC, an effect that we previously found to sensitize specifically PDAC/PSC coculture. Contrarily, LY294002 reduced p-Akt in PSC (hPSC and LTC-14) but had no impact on PSC radiation survival. In vitro, nelfinavir sensitized Panc-1 and PSN-1 under normoxic and hypoxic conditions. In PSN-1 xenografts, +PSC led to faster tumor regrowth after radiation vs −PSC. The regrowth delay effect of nelfinavir after radiation was dramatically larger +PSC vs −PSC (time to reach 250 mm 3 183% vs 22%). Conclusion: NFV mediated radiosensitization in PDAC with stroma is partly mediated by p-FAK inhibition (Chen et al., 2013). In vitro, NFV sensitizes both normoxic and hypoxic PDAC +/− PSC to a roughly similar extent. The dramatic increased effect of xenograft regrowth inhibition by nelfinavir in tumors with PSC is attributed to vascular normalization (Brunner et al., 2014) rather than direct modification of hypoxia as shown by the tumor regrowth after gemcitabine with NFV. … (more)
- Is Part Of:
- Radiotherapy and oncology. Volume 119:Issue 2(2016:May)
- Journal:
- Radiotherapy and oncology
- Issue:
- Volume 119:Issue 2(2016:May)
- Issue Display:
- Volume 119, Issue 2 (2016)
- Year:
- 2016
- Volume:
- 119
- Issue:
- 2
- Issue Sort Value:
- 2016-0119-0002-0000
- Page Start:
- 300
- Page End:
- 305
- Publication Date:
- 2016-05
- Subjects:
- Pancreatic cancer -- Radiotherapy -- Nelfinavir -- Pancreatic stellate cells -- Hypoxia
Oncology -- Periodicals
Radiotherapy -- Periodicals
Tumors -- Periodicals
Medical Oncology -- Periodicals
Neoplasms -- radiotherapy -- Periodicals
Radiotherapy -- Periodicals
Radiothérapie -- Périodiques
Cancérologie -- Périodiques
Tumeurs -- Périodiques
Electronic journals
616.9940642 - Journal URLs:
- http://www.sciencedirect.com/science/journal/01678140 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/01678140 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/01678140 ↗
http://www.estro.org/ ↗
http://www.elsevier.com/journals ↗
http://www.journals.elsevier.com/radiotherapy-and-oncology/ ↗ - DOI:
- 10.1016/j.radonc.2016.03.024 ↗
- Languages:
- English
- ISSNs:
- 0167-8140
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 7240.790000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 7631.xml